Our observation that the p53 protein—the major tumor suppressor in the human genome—is subject to fundamentally different regulation in the NMR as compared to all other species studied to date, suggests that elucidation of this atypical regulation may provide unique drug development strategies for cancer therapeutics. This evidence concerns the gene TP53 and neoplasm.